B-cell responses during primary and secondary dengue virus infections in humans

Journal of Infectious Diseases

Volumn 204, Issue 10, 2011, Pages 1514-1522

  Mathew, Anuja ^a   West, Kim ^a   Kalayanarooj, Siripen ^b   Gibbons, Robert V ^c   Srikiatkhachorn, Anon ^a   Green, Sharone ^a   Libraty, Daniel ^a   Jaiswal, Smita ^a   Rothman, Alan L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Queen Sirikit National Institute for Child Health   (Thailand)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; MEMBRANE PROTEIN; NONSTRUCTURAL PROTEIN 1;

ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CONTROLLED STUDY; CROSS REACTION; DENGUE; DENGUE VIRUS; DISEASE SEVERITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY INFECTION; PRIORITY JOURNAL; SECONDARY INFECTION; SEROTYPE;

ADOLESCENT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROSS REACTIONS; DENGUE; DENGUE VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; SEROTYPING; THAILAND; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 80054730869     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir607     Document Type: Article

References (36)

1. Pinheiro FP, Corber SJ. Global situation of dengue and dengue haemorrhagic fever, and its emergence in the Americas. World Health Stat Q 1997; 50:161-9. (Pubitemid 28133355)
2. Thein S, Aung MM, Shwe TN, et al. Risk factors in dengue shock syndrome. Am J Trop Med Hyg 1997; 56:566-72. (Pubitemid 27230081)
3. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2-9. (Pubitemid 30049026)
4. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis 1997; 176:322-30. (Pubitemid 27328753)
5. Halstead SB. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: A pathogenetic cascade. Rev Infect Dis 1989; 11:S830-9.
6. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003; 60:421-67. (Pubitemid 137639381)
7. Beasley DW, Holbrook MR, Travassos Da Rosa AP, et al. Use of a recombinant envelope protein subunit antigen for specific serological diagnosis of West Nile virus infection. J Clin Microbiol 2004; 42:2759-65. (Pubitemid 38747532)
8. Falconar AK. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/ adhesion proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Arch Virol 1997; 142:897-916. (Pubitemid 27218413)
9. Falconar AK. Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch Virol 1999; 144:2313-0.
10. Falconar AK. Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strains: implications for pathogenesis and vaccines. Clin Vaccine Immunol 2008; 15:549-61. (Pubitemid 351967084)
11. Falconar AK, Young PR. Miles MA. Precise location of sequential dengue virus subcomplex and complex B cell epitopes on the nonstructural-1 glycoprotein. Arch Virol 1994; 137:315-26. (Pubitemid 2133882)
12. Ludolfs D, Reinholz M. Schmitz H. Highly specific detection of antibodies to tick-borne encephalitis (TBE) virus in humans using a domain III antigen and a sensitive immune complex (IC) ELISA. J Clin Virol 2009; 45:125-8.
13. Oliphant T, Nybakken GE, Engle M, et al. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol 2006; 80:12149-59. (Pubitemid 44904366)
14. Sukupolvi-Petty S, Austin SK, Purtha WE, et al. Type-and subcomplexspecific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 2007; 81:12816-26. (Pubitemid 350156919)
15. Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 2001; 75:7769-73. (Pubitemid 32738039)
16. Roehrig JT. Antigenic structure of flavivirus proteins. Adv Virus Res 2003; 59:141-75. (Pubitemid 137640952)
17. Crill WD, Hughes HR, Delorey MJ. Chang GJ. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 2009; 4:e4991.
18. WahalaWM, Kraus AA, Haymore LB, Accavitti-Loper MA. de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 2009; 392:103-13.
19. Beltramello M, Williams KL, Simmons CP, et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010; 8:271-83.
20. Schieffelin JS, Costin JM, Nicholson CO, et al. Neutralizing and nonneutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol J 2010; 7:28.
21. Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010; 328:745-8.
22. Kalayanarooj S, Vaughn DW, Nimmannitya S, et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 1997; 176:313-21. (Pubitemid 27328752)
23. Endy TP, Nisalak A, Chunsuttitwat S, et al. Relationship of pre-existing dengue virus (DV) neutralizing antibody levels to viremia and disease severity in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004; 189:990-1000. (Pubitemid 38373090)
24. Midgley CM, Bajwa-Joseph M, Vasanawathana S, et al. An in-depth analysis of original antigenic sin in dengue virus infection. J Virol 2010; 85:410-21.
25. de Souza VA, Fernandes S, Araujo ES, et al. Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections. J Clin Microbiol 2004; 42:1782-4. (Pubitemid 38500840)
26. de Souza VA, Tateno AF, Oliveira RR, et al. Sensitivity and specificity of three ELISA-based assays for discriminating primary from secondary acute dengue virus infection. J Clin Virol 2007; 39:230-3. (Pubitemid 46907725)
27. Halliley JL, Kyu S, Kobie JJ, et al. Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization. Vaccine 2010; 28: 3582-7.
28. Lee FE, Falsey AR, Halliley JL, Sanz I, Walsh EE. Circulating antibodysecreting cells during acute respiratory syncytial virus infection in adults. J Infect Dis 2010; 202:1659-66.
29. Suryani S, Tangye SG. Therapeutic implications of advances in our understanding of transitional B-cell development in humans. Expert Rev Clin Immunol 2010; 6:765-75.
30. Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg 1952; 1:30-50.
31. Crotty S, Aubert RD, Glidewell J. Ahmed R. Tracking human antigenspecific memory B cells: A sensitive and generalized ELISPOT system. J Immunol Methods 2004; 286:111-22. (Pubitemid 38490401)
32. Duyen HT, Ngoc TV, Ha DT, et al. Kinetics of plasma viremia and soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune status. J Infect Dis 2011; 203:1292-300.
33. Yoshida T, Mei H, Dorner T, et al. Memory B and memory plasma cells. Immunol Rev 2010; 237:117-39.
34. da Silva AN, Nascimento EJ, Cordeiro MT, et al. Identification of continuous human B-cell epitopes in the envelope glycoprotein of dengue virus type 3 (DENV-3). PLoS One 2009; 4:e7425.
35. Baer J, Santiago F, Yang H, et al. B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variant. Vaccine 2010; 28:907-15.
36. Roehrig JT, Hombach J. Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008; 21:123-32. (Pubitemid 351873374)